Gene editing, mRNA vaccines and cell therapies all depend on a reliable supply of high-quality DNA, and traditional bacterial fermentation is widely seen as slow and cumbersome. 4basebio (AIM: 4BB), a Cambridge company, positions itself squarely at that bottleneck — manufacturing synthetic DNA without living cells and developing its own delivery technology. The proposition is compelling on paper; the gap between an attractive platform and a proven commercial business is what this piece digs into.

The Quick Version

  • 4basebio sells cell-free enzymatic synthetic DNA (opDNA) and is developing the Hermes non-viral delivery platform for gene therapy and DNA vaccines.
  • FY2025 revenue grew 81% to £1.7m, but the company reported a £16.9m net loss and held £17.8m of cash at 31 December 2025.
  • An April 2026 drawdown from the Deutsche Balaton facility is stated to extend the funding runway into late 2027.
  • Clinical traction includes a Tier 1 pharma partner dosing an mRNA programme and a post-period seven-figure Phase II immunotherapy supply agreement.
  • The investment case hinges on unproven commercial scale-up, continued cash consumption and a competitive, fast-moving synthetic biology market.

What 4basebio Actually Does

4basebio manufactures synthetic DNA using an enzymatic, cell-free process — marketed as opDNA, and in compact form as hpDNA — for use in mRNA production, gene editing, viral vectors and DNA vaccines. It's also developing Hermes, a non-viral delivery platform pitched as an alternative to lipid nanoparticles. The company traces its roots to the former Expedeon group, formed in Cambridge and admitted to AIM in February 2021; its shares are denominated in euros, a legacy of that continental heritage.

A significant regulatory step came in April 2025, when 4basebio obtained a Manufacturer's Authorisation for Investigational Medicinal Products plus GMP certification from the UK's MHRA — a threshold that separates a research-reagent supplier from a qualified clinical manufacturer.

Genuine Clinical Traction, Still Early

In October 2025 the company reported that an unnamed global Tier 1 pharmaceutical partner had begun dosing patients in a Phase I/II trial using an opDNA template for mRNA production, building on a supply relationship dating from April 2024. Then, alongside its FY2025 results in May 2026, 4basebio announced a multi-year clinical supply agreement, described as generating seven-figure revenue, supporting a Phase II trial of an unnamed cancer immunotherapy developer.

A January 2025 joint development agreement with Norway's Circio combines its circVec circular-RNA system with 4basebio's opDNA/hpDNA formats and the Hermes platform — an early research partnership rather than a commercial supply contract, with no financial terms disclosed.

New Leadership, Reshaped Business

Dr Manja Boerman was appointed Executive Chair in July 2025, and Dr Amy Walker became CEO in February 2026, succeeding founder Dr Heikki Lanckriet, who moved to a non-executive role. The company has also added a chief commercial officer, chief operating officer and, from mid-2026, a new CFO — changes management frames as building a more commercially oriented organisation.

The Numbers: Growth From a Small Base

For FY2025, revenue was £1.7m, up 81% on £0.9m in 2024, with clinical-stage project revenue rising to £1.1m from £0.5m. Losses widened though: an operating loss of £17.6m and net loss of £16.9m, versus £12.3m the prior year. Cash fell to £17.8m at 31 December 2025 from £34.6m a year earlier — a substantial rate of consumption as the company invests in capacity and headcount.

In April 2026, 4basebio drew €7m from a facility provided by its largest shareholder, Deutsche Balaton, which management states extends the funding runway into late 2027. A planned new innovation and manufacturing site in Cambridge, targeted for late summer 2026, commits capital ahead of the revenue needed to support it.

The Market Opportunity, and the Competition

The logic rests on growth in cell and gene therapy, mRNA and DNA-based medicines all requiring large quantities of high-quality DNA. The company reported serving more than 125 customers and partners and supporting four investigational new drug or clinical trial applications by end-2025. Translating that engagement into recurring, high-volume orders is the unresolved question.

Enzymatic and cell-free DNA synthesis is an active field with several private and public competitors, and established plasmid DNA manufacturers still serve the bulk of clinical demand. On delivery, lipid nanoparticle technology is well entrenched from approved mRNA vaccines, so Hermes must displace an incumbent standard rather than fill an empty space.

Risks Worth Weighing

The company remains loss-making and cash-consuming, and its stated runway into late 2027 assumes execution broadly to plan — any shortfall could bring forward a financing event, with dilution risk. Revenue is small and lumpy, with individual supply agreements capable of materially swinging figures. Much of the clinical traction depends on unnamed third-party partners whose programmes 4basebio doesn't control. Hermes is unproven in humans and faces an entrenched competitor. Currency effects, given euro-denominated shares and sterling reporting, add a further layer of complexity.

What to Watch Next

Additional multi-year clinical supply agreements, particularly with named or larger partners. Progression of existing partner trials to later phases or positive data read-outs. Successful, on-budget commissioning of the new Cambridge facility. Any first meaningful clinical use of Hermes. Continued revenue momentum and, over time, evidence of narrowing losses.